This study is accepting new patients by invitation only

Hemi-Gland Cryoablation for Prostate Cancer at UCLA

a study on Prostate Cancer Prostate Disease

Summary

Eligibility
for males (full criteria)
Location
at Los Angeles, California
Dates
study started
completion around
Principal Investigator
by Leonard S Marks, MD

Description

Summary

This is a prospective data collection of men who are electing to undergo prostate hemi-gland cryoablation.

The purpose of this observational research study is to investigate the localized treatment of prostate cancer using hemi-gland cryoablation.

UCLA patients undergoing hemi-gland cryoablation are a unique cohort compared to prior research because all patients at UCLA have had a pre-treatment multi-parametric MRI and Ultrasound fusion targeted biopsy; they will be followed in a similar fashion. This results in more precise assessment of a target region of cancer for ablation which may, in turn, result in improved clinical outcomes.

Official Title

Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at University of California at Los Angeles (UCLA)

Keywords

Prostate Cancer, Prostate Adenocarcinoma, Prostate Disease, cryoablation, Prostatic Neoplasms, Prostatic Diseases, Hemigland Cryoablation

Eligibility

You can join if…

Open to males

  • Patient has undergone or has elected to undergo hemi-gland cryoablation at UCLA
  • Low or intermediate risk prostate cancer (Gleason ≤ 7) or select high-risk patients (Gleason 8 prostate cancer).
  • Prostate volume of ≤ 70 cc
  • Ability to complete informed consent form

You CAN'T join if...

  • Medical contraindication to follow-up multi-parametric magnetic resonance imaging (mpMRI) or prostate biopsy
  • Patients unable to tolerate general or regional anesthesia.

Location

  • University of California, Los Angeles
    Los Angeles California 90095 United States

Lead Scientist at UCLA

  • Leonard S Marks, MD
    Dr. Leonard Marks holds the Jean B. deKernion, M.D., Endowed Chair in Urology.

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT03503643
Study Type
Observational
Participants
Expecting 100 study participants
Last Updated